TOPIC: 2021 American Transplant Congress

Bamlanivimab for Covid-19 in Kidney Transplant Patients
M. Y. Jan, S. El-Sayegh, M. S. Yaqub, D. P. Mishler, O. Adebiyi, M. D. Anderson, T. E. Taber, A. Sharfuddin
Barriers to Living Kidney Donation: A Closer Look at Declined Donors
M. Anand, S. Barhorst, S. Bumb, B. Abu Jawdeh, T. Kaur, A. Govil
Baseline Levels of Dd-cf Dna After Pancreas Transplantation: Using Dd-cfdna as an Indicator for Pancreas Rejection and Biopsy Avoidance
A. Yoo, I. Qian, A. Riedel, C. Cazac, A. Bartosic, J. S. Bromberg, J. Scalea
Basiliximab versus Alemtuzumab: The Association Between Induction Agent and Airway Complications Following Lung Transplantation
M. Furukawa¹, E. G. Chan¹, T. Harano¹, J. Ryan¹, R. Rivosecchi², M. R. Morrell¹, P. G. Sanchez¹
Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model
J. Kwun¹, R. Schmitz¹, M. Manook¹, Z. Fitch¹, D. Olaso¹, A. Choi¹, J. Yoon¹, Y. Bae¹, J. Lambris², S. Knechtle¹
Belatacept and Rapamycin Maintenance Immunosuppression in a Sensitized Nonhuman Primate Kidney Allotransplantation Model
R. Schmitz¹, Z. W. Fitch¹, M. Manook¹, J. Yoon¹, A. B. Farris², J. Kwun¹, S. J. Knechtle¹
Belatacept Conversion in Elderly Renal Transplant Recipients
M. Durst¹, D. Felix¹, M. Jorgenson¹, J. Descourouez¹, B. C. Astor², D. Mandelbrot²
Belatacept Conversion in Proteinuric Renal Transplant Recipients: An Interventional Multi-Center Trial
O. Efe¹, A. Al Jurdi¹, D. Wojciechowski², K. Safa¹, H. Gilligan¹, A. Chandraker³, J. Azzi³, A. Weins³, L. V. Riella¹
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
Belatacept for Kidney Transplantation in the Age of Covid19, is it Safe?
J. Pagan¹, S. Anjan², Y. Natori³, A. Fernandez³, R. Zamora-Gonzalez², A. Mattiazzi¹, L. Mendez¹, G. Guerra¹